Lykan Bioscience: RoslinCT and Lykan Bioscience to establish global advanced cell and gene therapy CDMO service offerings

RoslinCT and Lykan Bioscience announce their integration, creating a unified business that will operate under the RoslinCT brand. The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market. RoslinCT traces its roots back to the historic cloning ...